Search
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalLemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. … [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to
Vibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigational_Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. … prevention to become available in the U.S.
Procyclidine
go.drugbank.com/drugs/DB00387ApprovedInvestigationalA muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigational[L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood … Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: ANAGRELID AL 0.5MG HKPDroxicam
go.drugbank.com/drugs/DB09215ApprovedWithdrawnDroxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554]. … It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.
Phenyltoloxamine
go.drugbank.com/drugs/DB11160ApprovedPhenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. … Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.
Mixtures: Sinutab Sa TabResorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalIt is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses … Resorcinol is a 1,3-isomer (or meta-isomer) of benzenediol with the formula C6H4(OH)2.